Melanoma News and Research

Latest Melanoma News and Research

Cancer Research UK launches new cancer centre in Leeds

LEEDS today joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

18 May 2010

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Large number of people do not see health-care provider for skin cancer screening: Survey

Despite the fact that skin cancer is the only cancer that can be seen on the surface of the skin, a new survey by the American Academy of Dermatology reports that a large number of people are not taking the time to examine their skin for any changes that could be warning signs of skin cancer or seeing a health-care provider for a skin cancer screening.

17 May 2010

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

Saint John's Health Center Trustee and philanthropist Patrick Soon-Shiong, M.D., who developed the first FDA-approved protein nanoparticle treatment for cancer, has received the 2010 Distinguished Medical Science Award from the Friends of the National Library of Medicine for his significant contributions to the research and treatment of diabetes and cancer.

15 May 2010

3D test for diagnosing malignant melanoma

UK scientists have developed a 3D test for malignant melanoma that can identify problems not easily spotted in a standard two-dimensional view of the pattern on the skin. The researchers describe the technique in detail in the latest issue of the International Journal of Modelling, Identification and Control.

14 May 2010

Each melanoma cell capable of cancer stem cell behavior: Study

Scientists at The Wistar Institute offer a new explanation for the persistent ability of melanoma cells to self-renew, one of the reasons why melanoma remains the deadliest form of skin cancer. The concept of the "dynamic stemness" of melanoma can explain why melanoma cells behave like both conventional tumor cells and cancer stem cells.

14 May 2010

Genta first-quarter net loss increases to $166.6 million

Genta Incorporated today announced financial results for the quarter ended March 31, 2010.

13 May 2010

Researchers to discuss various implications for personalized medicine during one-day symposium

On May 27, researchers with the National Human Genome Research Institute and the National Cancer Institute, along with Group Health Cooperative in Seattle and Henry Ford Health System, will debate and discuss that question during the one-day symposium "Multiplex Initiative: Implications for Personalized Medicine."

13 May 2010

Melanoma is becoming increasingly common: Mayo Clinic Women's HealthSource

Melanoma -- the most serious form of skin cancer -- is becoming increasingly common, according to the May issue of Mayo Clinic Women's HealthSource.

13 May 2010

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Vical Incorporated announced the publication in the June issue of Melanoma Research of updated data from the company's Phase 2 trial of high-dose (2 mg) Allovectin-7® in patients with metastatic melanoma. A separate article in the May issue of Expert Opinion on Biological Therapy reviewed results from the Phase 2 trial and previous clinical studies of Allovectin-7®.

12 May 2010

Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, is pleased to announce it has signed a worldwide non-exclusive licensing agreement with the National Institutes of Health ('NIH'), a division of the U.S. Department of Health and Human Services, for use of the melanoma antigens TRP-2 and gp100, key components of Scancell's lead ImmunoBody® vaccine for melanoma, SCIB1.

11 May 2010

More genetic sites associated with increase in breast cancer risk discovered

Scientists have found five new regions of the genome that increase a woman's risk of developing breast cancer by between six and 16 per cent, according to a study in Nature Genetics today (Sunday)1.

10 May 2010

Majority of Americans concerned about skin cancer but still like tans

When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer.

10 May 2010

Majority of people like suntan but concerned about skin cancer

10 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

The Burnier International Ocular Pathology Society is holding a Scientific Colloquium in Montreal today to mark the tenth anniversary of the McGill University Health Centre's Henry C. Witelson Ocular Pathology Laboratory. The lab is an internationally reputed centre for the study and treatment of eye diseases and is leading a global network for the sharing of healthcare knowledge and expertise.

7 May 2010

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

6 May 2010

Melanoma News and Research

Latest Melanoma News and Research

Cancer Research UK launches new cancer centre in Leeds

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Large number of people do not see health-care provider for skin cancer screening: Survey

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

3D test for diagnosing malignant melanoma

Each melanoma cell capable of cancer stem cell behavior: Study

Genta first-quarter net loss increases to $166.6 million

Researchers to discuss various implications for personalized medicine during one-day symposium

Melanoma is becoming increasingly common: Mayo Clinic Women's HealthSource

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens

More genetic sites associated with increase in breast cancer risk discovered

Majority of Americans concerned about skin cancer but still like tans

Majority of people like suntan but concerned about skin cancer

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Vical reports net loss of $8.5 million for first-quarter 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Melanoma News and Research

Latest Melanoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in